Associated Papers
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC et al.
Molecular Diagnosis & Therapy, 2021
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]
Kurbat MN et al.
Eksperimental'naia I Klinicheskaia Farmakologiia, 2016
Warfarin pharmacogenetics.
Johnson JA et al.
Trends in Cardiovascular Medicine, 2015
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004
Select a paper to view details